ZURICH, June 16 (Reuters) - Actelion said its experimental heart and lung drug Selexipag met its primary goal in a late-stage study, giving the Swiss biotech company a potential second big seller to replenish its pipeline.
Results of the Phase III study involving 1,156 patients found that Selexipag prolonged life by 39 percent versus placebo in patients suffering from pulmonary arterial hypertension (PAH).
Selexipag is the third drug from Actelion to treat PAH, a progressively worsening condition characterised by abnormally high blood pressure in the arteries of the lungs. The cause is unknown and the disease has no cure. (Reporting by Caroline Copley; Editing by Michael Urquhart)